Articles by J. J.P Kastelein (5)

Chylomicronemia With a Mutant GPIHBP1 (Q115P) That Cannot Bind Lipoprotein Lipase

A. P Beigneux, R Franssen, A Bensadoun, P Gin, K Melford, J Peter, R. L Walzem, M. M Weinstein, B. S.J Davies, J. A Kuivenhoven, J. J.P Kastelein, L. G Fong, G. M Dallinga Thie and S. G. Young

Arteriosclerosis, Thrombosis, and Vascular Biology 29 ( 6 ): 956 - 962 , 2009

Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-{kappa}B Ligand and Risk for Coronary Events: A Nested Case-Control Approach in the Prospective EPIC-Norfolk Population Study 1993-2003

A. G Semb, T Ueland, P Aukrust, N. J Wareham, R Luben, L Gullestad, J. J.P Kastelein, K. T Khaw and S. M. Boekholdt

Arteriosclerosis, Thrombosis, and Vascular Biology 29 ( 6 ): 975 - 980 , 2009

Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms

R Sofat, A. D Hingorani, L Smeeth, S. E Humphries, P. J Talmud, J Cooper, T Shah, M. S Sandhu, S. L Ricketts, S. M Boekholdt, N Wareham, K. T Khaw, M Kumari, M Kivimaki, M Marmot, F. W Asselbergs, P van der Harst, R. P.F Dullaart, G Navis, D. J van Veldhuisen, W. H Van Gilst, J. F Thompson, P McCaskie, L. J Palmer, M Arca, F Quagliarini, C Gaudio, F Cambien, V Nicaud, O Poirer, V Gudnason, A Isaacs, J. C.M Witteman, C. M van Duijn, M Pencina, R. S Vasan, R. B D'Agostino, J Ordovas, T. Y Li, S Kakko, H Kauma, M. J Savolainen, Y. A Kesaniemi, A Sandhofer, B Paulweber, J. V Sorli, A Goto, S Yokoyama, K Okumura, B. D Horne, C Packard, D Freeman, I Ford, N Sattar, V McCormack, D. A Lawlor, S Ebrahim, G. D Smith, J. J.P Kastelein, J Deanfield and J. P. Casas

Circulation 121 ( 1 ): 52 - 62 , 2010

Prolactin Levels and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women

A. Q Reuwer, M. T Twickler, B. A Hutten, F. W Molema, N. J Wareham, G. M Dallinga Thie, R. L Bogorad, V Goffin, M Smink Bol, J. J.P Kastelein, S. M Boekholdt and K. T. Khaw

Circulation: Cardiovascular Genetics 2 ( 4 ): 389 - 395 , 2009

Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)

P. M Ridker, F. A.H Fonseca, J Genest, A. M Gotto, J. J.P Kastelein, W Koenig, P Libby, A. J Lorenzatti, B. G Nordestgaard, J Shepherd, J. T Willerson, R. J Glynn and for the JUPITER Study Group

Circulation: Cardiovascular Quality and Outcomes 2 ( 6 ): 616 - 623 , 2009